Tag Archive for: psychedelics

Psychedelics as Medicine: Expert Interview with Dr. Henrik Jungaberle in the “Psych Report 2021”

DO PSYCHEDELICS REALLY HAVE THE POWER TO DISRUPT HEALTHCARE? IF SO, HOW?

The Psychedelics as Medicine Report: Third Edition (2021) is an industry report outlet. It describes itself as “a premium business-to-business media and content platform for the psychedelic science and healthcare industry. Part of Psych Capital Plc.”. As such it tries to collect “consumer insights and market intelligence from experts and industry leaders, helping investors cut through the noise and identify real opportunities.”
Dr. Henrik Jungaberle has been interviewed for the report by Floris Wolswijk. Henrik is not involved with and has not been paid for the interview by either of the parties who produced or sponsored the report. His views are his own.

Video: Karin’s depression treatment at the OVID Practice Berlin (SWR1 – “What’s good about … drugs?”)

Pharmacologically based long-term therapies are often the treatment of choice for depression. Augmented psychotherapy, which uses mind-altering substances such as ketamine, is a new approach to helping depressed people. The altered states of consciousness induced in this way are then therapeutically integrated This treatment method, which is still relatively new in Germany, is the focus of Dr. med. Andrea Jungaberle and her colleagues in their clinic in Berlin Friedrichshain. Esanum visited the interdisciplinary team and informed us about the innovative procedure.
The esanum physician network has made a video report about the newly opened OVID Clinic Berlin. In it, Andrea Jungaberle, MD, Sergio Pérez and members of the team of therapists present the concept for psychedelic-augmented psychotherapy. Augmented means “amplified, expanded, intensified”.

Special Issue of Pharmacopsychiatry on Psychedelics in Psychiatry 2021 – the characteristics of disruptive treatments

Special Issue of Pharmacopsychiatry on Psychedelics in Psychiatry 2021 – Gerhard Gründer and Henrik Jungaberle on the difference of disruptive treatments


Henrik Jungaberle

Cover Pharmacopsychiatry Psychedelics 2021.jpg


A special issue of Pharmacopsychiatry

„Psychedelics in Psychiatry 2021“

The July 2021 special issue of Psychopharmacology is dedicated to the renaissance of psychedelics in psychiatry that has occurred during the past couple of years. “Psychedelics in Psychiatry 2021” contains four interesting review articles on different aspects of its historic development and current research as treatment in mood disorders and its effects in psychotherapy.
Together with Gerhard Gründer Henrik Jungaberle has co-authored a paper on “The potential role of psychedelic drugs in mental health care of the future”.

Prof. Dr. Gerhard Gründer describes the scope of the special issue in his editoral:

“It is important to be aware of the historical roots of our current medical practices. This is particularly true of the use of psychedelics for medical purposes. Nichols and Walter in their thoughtful review provide an overview of the historical basis on which all current psychedelic treatment research is based [5]. Treatment with a psychedelic is not just the application of a pill. Rather, it must always be embedded in psychotherapeutic support. The scope and nature of this psychotherapeutic program are the subjects of intense research, the current status of which is presented in the overview by Nayak and Johnson [6]. What is the mechanism of action of psychedelics? The entire spectrum of psychological and biological processes that are triggered by psychedelics is the subject of the review by Mertens and Preller [7]. They discuss the current state of research using the example of 2 possible future therapeutic indications, affective and substance use disorders. Finally, psychedelic therapy not only requires a new infrastructure in which it is carried out but also must be integrated into the existing system and differentiated from the recreational use of these substances. Many social, political, and cultural questions are affected by this enculturation. The challenges of how psychedelics could be implemented in a future mental health care system are discussed by Gründer and Jungaberle [8].”

July, 15th, 2021






TV: Andrea Jungaberle urges caution in “Radical Ideals: Drugs? Legalize!” on SWR3/ARD Mediathek

This is how Gülseren Ölcüm phrases the content of her episode in the ARD Mediathek: “Drugs as a cure for the soul? Gülseren Ölcüm meets activists who use psychedelics to expand their consciousness. And doctors who want to use them to treat the mentally ill. They are fighting for easier access. Some of them go further than the law allows.”

Conference: INSIGHT 2021 – an invitation to Berlin. Psychedelic research, therapy and drug development in Berlin

At INSIGHT 2021, scientists and therapists, pharmaceutical industry and anthropology, philosophers, and chemists will come together to determine the potential place of LSD, psilocybin, DMT, MDMA, and other psychedelic substances in the treatment of mental disorders. In addition, we will discuss the use of non-pharmacological methods to alter and cultivate states of consciousness and all that it takes to build such unusual states of consciousness a legitimate and safe place in society.

Writing the histories of psychedelic research: Wirtschaftswoche on German LSD-Researcher Hanscarl Leuner

German journalist Marlene Halser on the LSD-researcher Hanscarl Leuner
“Psychedelic mushrooms are in demand on the stock market – this man paved the way for them” (Wirtschaftswoche)

For almost 30 years, Hanscarl Leuner treated people with LSD and psilocybin at the University Hospital in Göttingen. Substances in which highly valued start-ups are currently investing – while the German researcher has been relegated to the sidelines of society.”
… and a free link to “The History of Psychedelics in Psychiatry”

Video: Psychedelic therapy serious – The physician portal esanum reports about the OVID Clinic Berlin

Pharmacologically based long-term therapies are often the treatment of choice for depression. Augmented psychotherapy, which uses mind-altering substances such as ketamine, is a new approach to helping depressed people. The altered states of consciousness induced in this way are then therapeutically integrated This treatment method, which is still relatively new in Germany, is the focus of Dr. med. Andrea Jungaberle and her colleagues in their clinic in Berlin Friedrichshain. Esanum visited the interdisciplinary team and informed us about the innovative procedure.
The esanum physician network has made a video report about the newly opened OVID Clinic Berlin. In it, Andrea Jungaberle, MD, Sergio Pérez and members of the team of therapists present the concept for psychedelic-augmented psychotherapy. Augmented means “amplified, expanded, intensified”.

Radio: “”High sein” – Henrik Jungaberle on a new edition of the drug education book in Deutschlandfunk Corso

“For anyone who wants to get a differentiated picture”.
Alcohol, coke, pills – the list of available drugs is long, and so is the list of addictions. “Being High” is a handbook that casts a nuanced picture on drugs of all kinds. “We have a very dysfunctional relationship with the people who use them,” author Henrik Jungaberle told Dlf.

Henrik Jungaberle in a Corso conversation with Ulrich Biermann

Podcast: Drugs are the answer to what question after all? Henrik Jungaberle in Wieprechts Truths

Drugs are the answer to what questions yet the same?

In a conversation with scientist and drug expert Henrik Jungaberle, Volker Wieprecht rethinks his plan to celebrate his 75th birthday with an opium intoxication. Why actually drugs and if so, for what purpose?

Wieprecht’s Wahrheiten is a podcast for everyone who wants to explore (with him) the deeper meaning of life.

Podcast: Henrik in conversation with Darek Dwanda on values and programs of the MIND Foundation

Berlin’s MIND Foundation is one of Europe’s largest psychedelic therapy organizations with global aspirations. MIND has a range of amazing programs for therapists, academics, and anyone else interested in new psychedelic therapies. In this episode we discuss a range of issues including European psychedelic landscape, ethics of Psychedelic-Assisted Therapies, cultural issues, issues of growth, and many other issues related to healing with psychedelics.